What Blood Tests Are Needed for JAK Inhibitors in Myelofibrosis?

Starting a JAK inhibitor is an important step in managing myelofibrosis, but these medications require regular monitoring to ensure they are working safely and effectively. The specific tests you need will depend on which JAK inhibitor you are taking—ruxolitinib, fedratinib, pacritinib, or momelotinib.

Your care team will use these tests to adjust your dose, manage side effects, and track how well the treatment is controlling your disease. Never stop, skip, or change the dose of your JAK inhibitor without medical guidance.

General Monitoring for All JAK Inhibitors

While each medication has unique requirements, there is a standard set of monitoring that applies to all JAK inhibitors used for myelofibrosis. Your care team will set a schedule tailored to your health.

• Complete Blood Count (CBC) with Differential and Platelets: This is the most critical test. The “differential” measures specific white blood cells, like neutrophils, which fight infections. JAK inhibitors can lower your red blood cells (causing anemia), platelets (increasing bleeding risk), and white blood cells (increasing infection risk) ^[1]. You will need a baseline CBC and then frequent checks—often every 2 to 4 weeks during early treatment, and periodically thereafter—so your care team can safely adjust your dose ^[1][2][3].
• Liver and Kidney Tests: Blood tests to check your kidney function (like creatinine) and liver enzymes are necessary before starting and periodically during treatment ^[4][5]. If you have severe liver or kidney impairment, your doctor may need to lower your starting dose ^[4][6].
• Infection and Vaccine Review: JAK inhibitors can suppress your immune system, increasing your risk of infections, including shingles ^[7][8]. Screening for prior infections (like hepatitis or tuberculosis) will be based on your medical history and local guidelines. Discuss vaccines with your doctor before starting treatment; non-live vaccines are often recommended, but live vaccines may be unsafe while on these therapies ^[7][3].
• Tracking Treatment Response: A successful response is about more than just spleen size. Doctors track improvements in your spleen size, symptom burden (like fatigue and night sweats), blood counts, and your need for transfusions ^[9][10]. Meaningful improvement is often assessed over several months of continuous treatment ^[11].
• Medication Safety Check: All JAK inhibitors can interact with other drugs. Have your team review every prescription, over-the-counter medicine, and supplement you take. Medicines that affect how the liver processes drugs (like certain antifungals or antibiotics) can dangerously increase JAK inhibitor levels ^[12][13].

Drug-Specific Monitoring Requirements

Your care team will order additional tests depending on your specific prescription.

Ruxolitinib (Jakafi)

Dose-dependent drops in blood counts are very common. Your medical team will closely monitor your CBC to manage anemia and low platelets through careful dose adjustments ^[2][1]. Vigilance for viral infections, particularly shingles, is highly emphasized ^[7].

Fedratinib (Inrebic)

• Thiamine (Vitamin B1) Monitoring: Fedratinib carries a boxed warning for Wernicke encephalopathy, a severe neurologic emergency linked to low thiamine. Any thiamine deficiency must be corrected before starting. Levels are checked at baseline and periodically during treatment, and prophylactic (preventative) thiamine supplements are often prescribed ^[14][15][16].
• Gastrointestinal and Nutrition Checks: Fedratinib frequently causes nausea, vomiting, and diarrhea. If these side effects lead to poor nutrition or dehydration, your risk of thiamine deficiency increases ^[16][17].
• Organ Function and Interactions: Liver enzymes and kidney function require monitoring; doses are reduced for severe kidney impairment ^[4][18]. If you must take a strong CYP3A4 inhibitor (like certain antifungals), your fedratinib dose must be reduced ^[13].

Pacritinib (Vonjo)

Pacritinib is FDA-approved for patients with severe thrombocytopenia (very low platelets) ^[19].

• Bleeding Risk: While designed for patients with low platelets, serious bleeding events have been reported. Clinical monitoring for bleeding is essential ^[20][21].
• Heart Rhythm (ECG): Pacritinib carries a warning for QT prolongation, an ECG finding where the heart’s electrical system takes longer to recharge, which can increase the risk of dangerous irregular rhythms ^[22]. Your doctor may use an electrocardiogram (ECG) to monitor this based on your personal risk factors.
• Medication Interactions: Strong CYP3A4 inhibitors (like specific antifungals) can significantly increase pacritinib levels in your blood and should be avoided or closely managed by your team ^[12][23].

Momelotinib (Ojjaara)

Momelotinib can help improve anemia while treating other myelofibrosis symptoms ^[9].

• Liver and Kidney Checks: If you have severe liver impairment, you will need a reduced dose (moderate impairment does not require a change) ^[5][6]. Real-world observations suggest that active monitoring of your kidney filtration rate is also a prudent part of your care ^[24][20].
• Neuropathy Monitoring: Peripheral neuropathy (numbness, tingling, or pain in your hands or feet) is a known potential side effect ^[24]. Your doctor will ask about new nerve symptoms during check-ups ^[20][25].
• Infection Vigilance: Momelotinib can increase the risk of serious infections (such as pneumonia), requiring ongoing clinical surveillance ^[25][26].

What to Watch For Between Appointments

Do not wait for your next scheduled test if you feel unwell.

Seek Emergency Medical Care (Call 911 or go to the ER) if you experience:

• Heavy or uncontrolled bleeding, or black/bloody stools.
• Chest pain, sudden shortness of breath, fainting, or severe palpitations.
• Sudden weakness, facial drooping, or difficulty speaking.
• For fedratinib: Sudden confusion, unsteady walking, balance issues, memory problems, or vision/eye movement changes (these are signs of Wernicke encephalopathy and require urgent medical intervention).

Call Your Clinic Urgently if you experience:

• Fever of 100.4°F (38°C) or higher, chills, or new rashes/skin lesions.
• Unusual bruising or pinpoint red spots on the skin.
• Severe nausea, vomiting, or diarrhea leading to dehydration (inability to keep fluids down).
• New numbness, tingling, or burning in your hands or feet (especially on momelotinib).